-
1
-
2di Holzmayer, Vera, Taylor, Russell, Kuhns, Mary C., Gawel, Susan H., Ndembi, Nicaise, Mbanya, Dora, Kaptue, Lazare, Rodgers, Mary A., Cloherty, Gavin“...We evaluated the use of DBS whole blood samples in the modified Abbott ARCHITECT anti-HCV assay, comparing assay performance against the standard assay run using DBS and venous plasma samples. 144 HCV positive and 104 HCV negative matched venous plasma and whole blood specimens were selected from a retrospective study with convenience sampling in Cameroon. ...”
Pubblicazione 2022
Testo
Testo
Testo
Online Articolo testo -
3di Rodgers, Mary A., Shah, Pir A., Anderson, Mark, Vallari, Ana S., Gersch, Jeffrey, Mbanya, Dora, Sauleda Oliveras, Silvia, Choudhry, Saad, Leary, Thomas P., Kuhns, Mary C., Dawson, George J., Cloherty, Gavin A., Lau, Daryl T.Y.“...To evaluate the clinical utility of HBsAg isoforms, we developed novel prototype assays on the ARCHITECT automated serology platform that specifically detects total-HBsAg (T-HBsAg), large (L-HBsAg), and middle (M-HBsAg) products of the S gene to determine the isoform composition of human specimens from acute and chronic HBV infection and during long-term nucleos(t)ide analog therapy. ...”
Pubblicazione 2023
Testo
Testo
Testo
Online Articolo testo -
4Development and performance of prototype serologic and molecular tests for hepatitis delta infectiondi Coller, Kelly E., Butler, Emily K., Luk, Ka-Cheung, Rodgers, Mary A., Cassidy, Michael, Gersch, Jeffrey, McNamara, Anne L., Kuhns, Mary C., Dawson, George J., Kaptue, Lazare, Bremer, Birgit, Wedemeyer, Heiner, Cloherty, Gavin A.“...Prototype molecular (RNA) and serologic (IgG) assays were developed for high-throughput testing on the Abbott m2000 and ARCHITECT systems, respectively. RNA detection was achieved through amplification of a ribozyme region target, with a limit of detection of 5 IU/ml. ...”
Pubblicazione 2018
Testo
Testo
Testo
Online Articolo testo -
5di Bazinet, Michel, Pântea, Victor, Cebotarescu, Valentin, Cojuhari, Lilia, Jimbei, Pavlina, Anderson, Mark, Gersch, Jeff, Holzmayer, Vera, Elsner, Carina, Krawczyk, Adalbert, Kuhns, Mary C., Cloherty, Gavin, Dittmer, Ulf, Vaillant, Andrew“...Supplemental analysis included high‐sensitivity HBsAg (Abbott ARCHITECT HBsAg NEXT), HBV pregenomic RNA (pgRNA), HBsAg/hepatitis B surface antibody (anti‐HBs) immune complexes (HBsAg ICs), and hepatitis B core‐related antigen (HBcrAg). ...”
Pubblicazione 2020
Testo
Testo
Testo
Online Articolo testo -
6di Kuhns, Mary C., Holzmayer, Vera, Anderson, Mark, McNamara, Anne L., Sauleda, Silvia, Mbanya, Dora, Duong, Pham T., Dung, Nguyen T. T., Cloherty, Gavin A.“...Methods: A total of 347 samples collected from the USA, South Africa, Spain, Cameroon, Vietnam, and Cote D’Ivoire representing NAT yield (HBsAg(−), antibody to HBV core antigen (anti-HBc)(−), HBV DNA(+), N = 131), OBI (HBsAg(−), anti-HBc(+), HBV DNA(+), N = 188), and HSLD (HBsAg(+), anti-HBc(+), HBV DNA(+), N = 28) were tested with ARCHITECT HBsAg NEXT (HBsAgNx) (sensitivity 0.005 IU/mL). ...”
Pubblicazione 2021
Testo
Testo
Testo
Online Articolo testo -
7di Kuhns, Mary C., Holzmayer, Vera, McNamara, Anne L., Anderson, Mark, Cloherty, Gavin A.“...Testing included quantitative hepatitis B surface antigen (HBsAg), antibodies to HBV antigens, quantitative HBV e antigen (HBeAg), HBV DNA, quantitative HBV core-related antigen (HBcrAg), the highly sensitive ARCHITECT HBsAg NEXT (HBsAgNx) assay, and a quantitative research assay for HBV pregenomic RNA (pg RNA). ...”
Pubblicazione 2021
Testo
Testo
Testo
Online Articolo testo